Data-driven stock valuation

Oric Pharmaceuticals Inc (ORIC) fair value: what the stock is really worth

We calculate from audited financials what Oric Pharmaceuticals Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

1. Compare price with fair valuebelow fair value = cheap, above = expensive
2. Check the quality50 and up solid, 75 and up strong
3. Watch it or check another stockalert when fair value or trend changes

Check any stock: type a name, ticker or ISIN

Healthcare · US · Market cap $1.5B · ISIN US68622P1093

At a glance

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case ($2.69). The favourable scenario is already priced in.
• Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range ($1.42 to $2.69) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.

How to read this chart

60‑month range $2.44 – $25.22 · fair‑value band $1.42 – $2.69 · the $12.50 price screens above the $2.15 fair value. Dashed = 300-day average. As of Aug 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Oric Pharmaceuticals Inc (ORIC) currently trades at $12.50, while our model-based Fair Value estimate is $2.15, implying the stock looks roughly 481.4% overvalued today. The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

It earns a return on equity of −42.6%. The balance sheet holds a net cash position of $34.1M. Fundamentals as of Aug 21, 2026

Scenario range: $1.42 (bear) to $2.69 (bull), the price of $12.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 16% below its 52-week high and 73% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −49% fair-value upside, at −83%, ORIC screens richer than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Key figures & financial health

Quality Score breakdown

About the company

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.

Full company description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Oric Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$129M in FY2025.

ORIC screens 481% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Peer Group

Biotechnology · 633 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Context: sector, industry, market

• Is the Health Care sector expensive or cheap?
• P/E, EV/EBITDA and margins by industry (reference tables)
• Undervalued stocks: US Stocks
• Valuation of the USA market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions